Alpha Centric Advisors LLC Sage Therapeutics, Inc. Transaction History

Alpha Centric Advisors LLC

  • $118 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 08, 2022
SELL
$32.28 - $43.27 $355,080 - $475,970
-11,000 Closed
0 $0
Q4 2021

Feb 25, 2022
BUY
$37.06 - $47.11 $185,300 - $235,550
5,000 Added 83.33%
11,000 $468,000
Q3 2021

Mar 09, 2022
BUY
$40.26 - $57.37 $241,560 - $344,220
6,000 New
6,000 $266,000

Others Institutions Holding SAGE

# of Institutions
198
Shares Held
46.5M
Call Options Held
402K
Put Options Held
209K
View Full List

About Sage Therapeutics, Inc.

SAGE Quotes by TradingView
  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $330M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email